July 22, 2014

Compounded Medications

Dear Pharmacist,

The Oklahoma Health Care Authority is evaluating policy for compounded prescription claims. An assessment of the peer reviewed literature regarding compounded topical medications containing multiple ingredients revealed that these products have shown limited, if any, clinical results or efficacy. OHCA has determined that there is insufficient evidence to support continued use of these products.

Effective Wednesday, July 30, 2014, OHCA will no longer cover the ingredients listed below which have been used in the compounding of topical creams and ointments. These ingredients are classified as Active Pharmaceutical Ingredients (APIs) which may be covered at the option of OHCA. There is no federal mandate for coverage.

The following powder APIs will no longer be covered:

- Ketamine
- Tramadol
- Gabapentin
- Cyclobenzaprine
- Diclofenac
- Baclofen

These ingredients in topical form have been shown to have limited benefit for members as FDA approved therapies are currently available to treat conditions associated with their use.

OHCA is currently reviewing the compounding policy and invites your comments. You may submit comments to Pharmacy@okhca.org or by fax to 405-530-7238.

Thank you for the services you provide to Oklahomans insured by SoonerCare!